CUROSURF (poractant alfa) is a surfactant intended only for intratracheal use ,indicated for the rescue treatment, including the reduction of mortality and pneumothoraces associated with Respiratory Distress Syndrome (RDS) in premature infants.
CUROSURF (poractant alfa) is a sterile, non-pyrogenic pulmonary surfactant. It is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C).
CUROSURF is a white to creamy white suspension of poractant alfa. Each milliliter of suspension contains 80 mg of poractant alfa (surfactant extract) that includes 76 mg of phospholipids and 1 mg of protein of which 0.45 mg is SP-B and 0.59 mg is SP-C.
Manufacturer : Abbott
Strengths available : 80mg, 120mg & 240mg
Form : Vials
Storage : Store at temperature between 2°C to 8°C
FDA Approval : U.S Approval
Date of Approval : 1999
Dosage : The initial recommended dose is 2.5 mL/kg birth weight (see Table 1), administered as one or two aliquots depending upon the instillation procedure.
Up to two repeat doses of 1.25 mL/kg birth weight each may be administered at approximately 12-hour intervals in infants who remain intubated and in whom RDS is considered responsible for their persisting or deteriorating respiratory status. The maximum recommended total dosage (sum of the initial and up to two repeat doses) is 5 mL/kg.
Most common side effects are Abnormally Low Blood Pressure , Slow Heartbeat , Bleeding From The Lungs, Decreased Oxygen In The Tissues Or Blood.